Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019
March 20 2019 - 4:20PM
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated
biopharmaceutical company focused on discovering and developing
novel vaccines and immuno-oncology therapeutics, today announced it
will present safety and biomarker data for DV281, its inhaled TLR9
agonist, at the American Association for Cancer Research (AACR)
Annual Meeting 2019, being held March 29 - April 3, in Atlanta,
Georgia.
Abstract Number and Title: #8304,
“Phase Ib/II, open label, multicenter study of inhaled DV281, a
Toll-like receptor 9 agonist, in combination with nivolumab in
patients with advanced or metastatic non-small cell lung cancer
(NSCLC)”
Poster Session Title: Phase I-III
Trials in Progress: Part 3
Session Date and Time: Tuesday,
April 2, 2019, 1 – 5 p.m. ET
Session Location: Georgia World
Congress Center, Exhibit Hall B, Poster Section 17, Poster Board
Number: #18
Permanent Abstract Number:
CT224
About DV281 DV281 is Dynavax's
proprietary investigational TLR9 agonist designed specifically for
focused delivery to primary lung tumors and lung metastases. DV281
is similar in biological activity and mechanism of action to
Dynavax's Phase 2 immunotherapy candidate, SD-101, but has been
optimized for administration as an inhaled therapy. Both SD-101 and
DV281 activate plasmacytoid dendritic cells which then stimulate T
cells specific for antigens released from dying tumor cells. TLR9
agonists such as DV281 and SD-101 have been shown to stimulate
potent Type 1 interferon induction along with maturation of
dendritic cells to effective antigen-presenting cells; both
activities are important for the induction of effective anti-tumor
immunity.
About Dynavax Dynavax is
a fully-integrated biopharmaceutical company focused on leveraging
the power of the body's innate and adaptive immune responses
through toll-like receptor (TLR)
stimulation. Dynavax discovers and develops novel
vaccines and immuno-oncology therapeutics. The Company’s first
commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant),
Adjuvanted], is approved in the U.S. for prevention of infection
caused by all known subtypes of hepatitis B virus in adults age 18
years and older. Dynavax's lead immunotherapy product,
SD-101, is an investigational cancer immunotherapeutic currently
being evaluated in Phase 1/2 studies and its second cancer
immunotherapeutic, DV281, is in Phase 1 development. For more
information, visit www.dynavax.com.
ContactHeather Rowe Vice
President, Investor Relations & Corporate Communications
510-665-7269
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From May 2023 to May 2024